PriceTargets.com logo

OTCMKTS:MMEDF - Mind Medicine (MindMed) Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.00
  • Forecasted Upside: -19.35 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.48 As of 10/21/2021 01:00 AM ET
▲ +0.11 (4.64%)

This chart shows the closing price for MMEDF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Mind Medicine (MindMed) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MMEDF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MMEDF

Analyst Price Target is $2.00
▼ -19.35% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Mind Medicine (MindMed) in the last 3 months. The average price target is $2.00, with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a -19.35% upside from the last price of $2.48.

This chart shows the closing price for MMEDF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Mind Medicine (MindMed).

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/2/2020Canaccord GenuityBoost Price TargetBuy$1.75 ➝ $2.00
9/15/2020Canaccord GenuityInitiated CoverageBuy
(Data available from 10/22/2016 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2021

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Mind Medicine (MindMed) logo
Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.
Read More

Today's Range

Now: $2.48
Low: $2.34
High: $2.49

50 Day Range

MA: $2.58
Low: $2.21
High: $3.11

52 Week Range

Now: $2.48
Low: $0.29
High: $5.07

Volume

2,659,107 shs

Average Volume

3,376,665 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Mind Medicine (MindMed)?

The following equities research analysts have issued stock ratings on Mind Medicine (MindMed) in the last twelve months: Canaccord Genuity.
View the latest analyst ratings for MMEDF.

What is the current price target for Mind Medicine (MindMed)?

1 Wall Street analysts have set twelve-month price targets for Mind Medicine (MindMed) in the last year. Their average twelve-month price target is $2.00, suggesting a possible downside of 19.4%. Canaccord Genuity has the highest price target set, predicting MMEDF will reach $2.00 in the next twelve months. Canaccord Genuity has the lowest price target set, forecasting a price of $2.00 for Mind Medicine (MindMed) in the next year.
View the latest price targets for MMEDF.

What is the current consensus analyst rating for Mind Medicine (MindMed)?

Mind Medicine (MindMed) currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MMEDF will outperform the market and that investors should add to their positions of Mind Medicine (MindMed).
View the latest ratings for MMEDF.

What other companies compete with Mind Medicine (MindMed)?

Other companies that are similar to Mind Medicine (MindMed) include (TNGN), 3SBio, 45525 (CUR.TO), Abattis Bioceuticals, Abzena, Acrux, Actinogen Medical, AdAlta, Admedus, Algernon Pharmaceuticals, Almirall, Amarantus BioScience, Amplia Therapeutics, Anatara Lifesciences and Annovis Bio.